Cytokine Signalling Forum

Cours de FMC




« Retour au menu principal

Highlights from ACR 2020: Psoriatic Arthritis

Highlights from ACR 2020: Psoriatic Arthritis
Developed by CESAS Medical, under the auspices of the University of Glasgow. This activity is supported by unrestricted educational grants from AbbVie, Gilead/Galapagos, Pfizer and Lilly.

Release date: 16 December 2020
Estimated time to complete activity: 1 hour
Compatible with all modern internet browsers and mobile devices

EDUCATIONAL OBJECTIVES
After completing this activity, the learner will:
  • Examine new data on JAK inhibitors and its clinical impact on psoriatic arthritis from ACR 2020
  • Evaluate the importance of patient-reported outcomes and the presence of pain in psoriatic arthritis

TARGET AUDIENCE
This activity is designed for qualified rheumatologists of all levels of seniority, and other healthcare professionals involved in treating patients with inflammatory disease.

PROGRAMME OVERVIEW
ACR 2020 presented new scientific and clinical information on cytokine signalling science that will shape the rheumatology treatment landscape. Data presented included new data on the role of JAK inhibitors in the treatment paradigm for psoriatic arthritis.

In this activity, Highlights from ACR 2020: Psoriatic Arthritis, international experts review and discuss key abstracts and data from ACR 2020 specifically relating to the outcomes of clinical trials of JAK inhibitors in psoriatic arthritis and real-world and patient-reported outcome data from psoriatic arthritis studies. In this course, the faculty also discuss pain in relation to the importance of patient-reported outcomes and the influence on patient treatment perspectives.

INSTRUCTIONS FOR PARTICIPATION
Participants must 1) read the activity information; 2) study the educational activity; 3) successfully complete the post-module assessments with a score of 80% or better; 4) and complete the evaluation form. Upon completion of the full activity, your certificate will be made available to download and print.

DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.

ACCREDITATION STATEMENT
The e-learning activity, Highlights from ACR 2020: COVID-19 and RA, organised by CESAS Medical, under the auspices of the University of Glasgow, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The e-learning activity, Highlights from ACR 2020: COVID-19 and RA, organised by CESAS Medical, under the auspices of the University of Glasgow, is awarded 1 European CME credits (ECMECs).

Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMS-EACCME website have formally been accredited. Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Module Présentateur Vidéo Questions
Introduction
Professor Philip Mease image
Professor Philip Mease

Director and Professor of Medicine,
University of Washington School of Medicine, Swedish Medical Center in Seattle, Washington, USA

Philip Mease is a Clinical Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Center in Seattle, Washington, US. His clinical practice is based at Seattle Rheumatology Associates.

Dr Mease obtained his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as Chief Resident and Fellow in Rheumatology.

As well as conducting clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus, he also conducts research in disease state metrics and is the Co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment. Dr Mease is also a member of the Soluble Biomarker working group.

Dr Mease is a founding organiser and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles, and serves as a reviewer for many journals including Arthritis & Rheumatism, Arthritis Care & Research, Annals of the Rheumatic Diseases, and Journal of Rheumatology. Dr Mease has been the recipient of the Medical Communicator Award of the American College of Rheumatology.

Prof. Philip Mease (Bio)
Clinical Outcomes in Trials of JAKs in PsA
Professor Atul Deodhar image
Professor Atul Deodhar

Professor of Medicine,
Oregon Health and Science University, Portland

Professor Atul A. Deodhar is Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland. He is board-certified in Internal Medicine and Rheumatology and is a Fellow of the American College of Rheumatology (ACR) and the American College of Physicians.

Professor Deodhar completed a fellowship in Rheumatology at Oregon Health & Science University and a research fellowship in Rheumatology at the Royal Cornwall Hospital in Truro, United Kingdom. He completed a residency in Internal Medicine and Geriatrics at the Royal Cornwall Hospital as well as at Sassoon General Hospital and King Edward Memorial Hospital in Pune, India. He received his medical degree from the University of Pune and is a member of the Royal College of Physicians in London, United Kingdom.

Professor Deodhar has authored three books, more than 250 peer-reviewed articles, and several book chapters and editorials. He is an incoming Editor-in-Chief of Best Practice and Research Clinical Rheumatology, a guest editor of Current Opinion in Rheumatology.

He has been a principal or coinvestigator in more than 100 clinical trials, mostly focused on therapies for ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis.

Professor Atul Deodhar (Bio)
27:27 3
Real World and Patient Reported Outcomes
Professor Philip Mease image
Professor Philip Mease

Director and Professor of Medicine,
University of Washington School of Medicine, Swedish Medical Center in Seattle, Washington, USA

Philip Mease is a Clinical Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Center in Seattle, Washington, US. His clinical practice is based at Seattle Rheumatology Associates.

Dr Mease obtained his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as Chief Resident and Fellow in Rheumatology.

As well as conducting clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus, he also conducts research in disease state metrics and is the Co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment. Dr Mease is also a member of the Soluble Biomarker working group.

Dr Mease is a founding organiser and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles, and serves as a reviewer for many journals including Arthritis & Rheumatism, Arthritis Care & Research, Annals of the Rheumatic Diseases, and Journal of Rheumatology. Dr Mease has been the recipient of the Medical Communicator Award of the American College of Rheumatology.

Prof. Philip Mease (Bio)
32:26 3
Close
Professor Philip Mease image
Professor Philip Mease

Director and Professor of Medicine,
University of Washington School of Medicine, Swedish Medical Center in Seattle, Washington, USA

Philip Mease is a Clinical Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Center in Seattle, Washington, US. His clinical practice is based at Seattle Rheumatology Associates.

Dr Mease obtained his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as Chief Resident and Fellow in Rheumatology.

As well as conducting clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus, he also conducts research in disease state metrics and is the Co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment. Dr Mease is also a member of the Soluble Biomarker working group.

Dr Mease is a founding organiser and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles, and serves as a reviewer for many journals including Arthritis & Rheumatism, Arthritis Care & Research, Annals of the Rheumatic Diseases, and Journal of Rheumatology. Dr Mease has been the recipient of the Medical Communicator Award of the American College of Rheumatology.

Prof. Philip Mease (Bio)
01:28
Evaluation 11

Date de préparation: 16 December 2020